Anti-hiv compounds

Patent metadata

Field	Value
Publication number	US-2025051375-A1
Application number	US-202418677586-A
Country	US
Kind code	A1
Filing date	May 29, 2024
Priority date	May 31, 2023
Publication date	Feb 13, 2025
Grant date	—

Abstract

The invention provides compounds having Formula (I):or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.

First claim

1 - 150 . (canceled)

151 . A compound selected from:

or a pharmaceutically acceptable salt thereof.

152 . The compound of claim 151 , which is

or a pharmaceutically acceptable salt thereof.

153 . The compound of claim 151 , which is

or a pharmaceutically acceptable salt thereof.

154 . The compound of claim 151 , which is

or a pharmaceutically acceptable salt thereof.

155 . The compound of claim 151 , which is

or a pharmaceutically acceptable salt thereof.

156 . The compound of claim 151 , which is

or a pharmaceutically acceptable salt thereof.

157 . A compound selected from:

158 . The compound of claim 157 , which is

159 . The compound of claim 157 , which is

160 . The compound of claim 157 , which is

161 . The compound of claim 157 , which is

162 . The compound of claim 157 , which is

163 . A pharmaceutical composition comprising the compound of claim 151 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

164 . A pharmaceutical composition comprising the compound of claim 157 , and a pharmaceutically acceptable excipient.

Assignees

• Gilead Sciences Inc

Inventors

• Brizgys Gediminas J
• Clarke Michael O’ Neil Hanrahan
• Fondekar Raheel
• Goyal Bindu
• Martinez Luisruben P
• Reid Bradley Thomas
• Shapiro Nathan D
• Tang Doris T

Classifications

• C07F9/65586 Primary

  at least one of the hetero rings does not contain nitrogen as ring hetero atom · CPC title

• A61P31/18

  for HIV · CPC title

• C07F9/6561 Primary

  containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title

• A61K31/675 Primary

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title